SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

Pilar Brito-Zerón; Sheila Melchor; Raphaèle Seror; Roberta Priori; Roser Solans; Belchin Kostov; Chiara Baldini; Francesco Carubbi; Jose Luis Callejas; Pablo Guisado-Vasco; Gabriela Hernández-Molina; Sandra G. Pasoto; Valeria Valim; Antoni Sisó-Almirall; Xavier Mariette; Patricia Carreira; Manuel Ramos-Casals; P. Brito-Zerón; C. Morcillo; P. Brito-Zerón; A. Flores-Chávez; N. Acar-Denizli; I. F. Horvath; A. Szanto; T. Tarr; R. Seror; T. Mandl; P. Olsson; X. Li; B. Xu; C. Baldini; S. Bombardieri; J. E. Gottenberg; S. Gandolfo; S. De Vita; R. Priori; F. Giardina; G. Hernandez-Molina; J. Sánchez-Guerrero; A. A. Kruize; A. Hinrichs; V. Valim; D. Isenberg; R. Solans; M. Rischmueller; S. Downie-Doyle; S. K. Kwok; S. H. Park; G. Nordmark; Y. Suzuki; M. Kawano; R. Giacomelli; V. Devauchelle-Pensec; A. Saraux; B. Hofauer; A. Knopf; H. Bootsma; A. Vissink; J. Morel; C. Vollenveider; F. Atzeni; S. Retamozo; V. Moça Trevisano; B. Armagan; L. Kilic; U. Kalyoncu; S. G. Pasoto; B. Kostov; A. Sisó-Almirall; S. Consani-Fernández; F. Carubbi; J. L. Callejas; M. López-Dupla; R. Pérez-Alvarez; M. Akasbi; I. Sánchez

doi:10.1093/rheumatology/keaa748

SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients

Pilar Brito-Zerón, Sheila Melchor, Raphaèle Seror, Roberta Priori, Roser Solans, Belchin Kostov, Chiara Baldini, Francesco Carubbi, Jose Luis Callejas, Pablo Guisado-Vasco, Gabriela Hernández-Molina, Sandra G. Pasoto, Valeria Valim, Antoni Sisó-Almirall, Xavier Mariette, Patricia Carreira, Manuel Ramos-Casals, P. Brito-Zerón, C. Morcillo, P. Brito-ZerónA. Flores-Chávez, N. Acar-Denizli, I. F. Horvath, A. Szanto, T. Tarr, R. Seror, T. Mandl, P. Olsson, X. Li, B. Xu, C. Baldini, S. Bombardieri, J. E. Gottenberg, S. Gandolfo, S. De Vita, R. Priori, F. Giardina, G. Hernandez-Molina, J. Sánchez-Guerrero, A. A. Kruize, A. Hinrichs, V. Valim, D. Isenberg, R. Solans, M. Rischmueller, S. Downie-Doyle, S. K. Kwok, S. H. Park, G. Nordmark, Y. Suzuki, M. Kawano, R. Giacomelli, V. Devauchelle-Pensec, A. Saraux, B. Hofauer, A. Knopf, H. Bootsma, A. Vissink, J. Morel, C. Vollenveider, F. Atzeni, S. Retamozo, V. Moça Trevisano, B. Armagan, L. Kilic, U. Kalyoncu, S. G. Pasoto, B. Kostov, A. Sisó-Almirall, S. Consani-Fernández, F. Carubbi, J. L. Callejas, M. López-Dupla, R. Pérez-Alvarez, M. Akasbi, I. Sánchez

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

18 Citations (Scopus)

Résumé

Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.

langue originale	Anglais
Pages (de - à)	2946-2957
Nombre de pages	12
journal	Rheumatology
Volume	60
Numéro de publication	6
Les DOIs	https://doi.org/10.1093/rheumatology/keaa748
état	Publié - 1 juin 2021

Accès au document

10.1093/rheumatology/keaa748

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

Brito-Zerón, P., Melchor, S., Seror, R., Priori, R., Solans, R., Kostov, B., Baldini, C., Carubbi, F., Callejas, J. L., Guisado-Vasco, P., Hernández-Molina, G., Pasoto, S. G., Valim, V., Sisó-Almirall, A., Mariette, X., Carreira, P., Ramos-Casals, M., Brito-Zerón, P., Morcillo, C., ... Sánchez, I. (2021). SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients. Rheumatology, 60(6), 2946-2957. https://doi.org/10.1093/rheumatology/keaa748

@article{147c807ec4694bda82dc7c025ffc9bdc,

title = "SARS-CoV-2 infection in patients with primary Sj{\"o}gren syndrome: Characterization and outcomes of 51 patients",

abstract = "Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sj{\"o}gren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.",

keywords = "COVID-19, Primary SS, SARS-Cov-2, comorbidities, outcomes",

author = "Pilar Brito-Zer{\'o}n and Sheila Melchor and Rapha{\`e}le Seror and Roberta Priori and Roser Solans and Belchin Kostov and Chiara Baldini and Francesco Carubbi and Callejas, {Jose Luis} and Pablo Guisado-Vasco and Gabriela Hern{\'a}ndez-Molina and Pasoto, {Sandra G.} and Valeria Valim and Antoni Sis{\'o}-Almirall and Xavier Mariette and Patricia Carreira and Manuel Ramos-Casals and P. Brito-Zer{\'o}n and C. Morcillo and P. Brito-Zer{\'o}n and A. Flores-Ch{\'a}vez and N. Acar-Denizli and Horvath, {I. F.} and A. Szanto and T. Tarr and R. Seror and T. Mandl and P. Olsson and X. Li and B. Xu and C. Baldini and S. Bombardieri and Gottenberg, {J. E.} and S. Gandolfo and {De Vita}, S. and R. Priori and F. Giardina and G. Hernandez-Molina and J. S{\'a}nchez-Guerrero and Kruize, {A. A.} and A. Hinrichs and V. Valim and D. Isenberg and R. Solans and M. Rischmueller and S. Downie-Doyle and Kwok, {S. K.} and Park, {S. H.} and G. Nordmark and Y. Suzuki and M. Kawano and R. Giacomelli and V. Devauchelle-Pensec and A. Saraux and B. Hofauer and A. Knopf and H. Bootsma and A. Vissink and J. Morel and C. Vollenveider and F. Atzeni and S. Retamozo and {Mo{\c c}a Trevisano}, V. and B. Armagan and L. Kilic and U. Kalyoncu and Pasoto, {S. G.} and B. Kostov and A. Sis{\'o}-Almirall and S. Consani-Fern{\'a}ndez and F. Carubbi and Callejas, {J. L.} and M. L{\'o}pez-Dupla and R. P{\'e}rez-Alvarez and M. Akasbi and I. S{\'a}nchez",

note = "Publisher Copyright: {\textcopyright} 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected].",

year = "2021",

month = jun,

day = "1",

doi = "10.1093/rheumatology/keaa748",

language = "English",

volume = "60",

pages = "2946--2957",

journal = "Rheumatology",

issn = "1462-0324",

number = "6",

}

Brito-Zerón, P, Melchor, S, Seror, R, Priori, R, Solans, R, Kostov, B, Baldini, C, Carubbi, F, Callejas, JL, Guisado-Vasco, P, Hernández-Molina, G, Pasoto, SG, Valim, V, Sisó-Almirall, A, Mariette, X, Carreira, P, Ramos-Casals, M, Brito-Zerón, P, Morcillo, C, Brito-Zerón, P, Flores-Chávez, A, Acar-Denizli, N, Horvath, IF, Szanto, A, Tarr, T, Seror, R, Mandl, T, Olsson, P, Li, X, Xu, B, Baldini, C, Bombardieri, S, Gottenberg, JE, Gandolfo, S, De Vita, S, Priori, R, Giardina, F, Hernandez-Molina, G, Sánchez-Guerrero, J, Kruize, AA, Hinrichs, A, Valim, V, Isenberg, D, Solans, R, Rischmueller, M, Downie-Doyle, S, Kwok, SK, Park, SH, Nordmark, G, Suzuki, Y, Kawano, M, Giacomelli, R, Devauchelle-Pensec, V, Saraux, A, Hofauer, B, Knopf, A, Bootsma, H, Vissink, A, Morel, J, Vollenveider, C, Atzeni, F, Retamozo, S, Moça Trevisano, V, Armagan, B, Kilic, L, Kalyoncu, U, Pasoto, SG, Kostov, B, Sisó-Almirall, A, Consani-Fernández, S, Carubbi, F, Callejas, JL, López-Dupla, M, Pérez-Alvarez, R, Akasbi, M & Sánchez, I 2021, 'SARS-CoV-2 infection in patients with primary Sjögren syndrome: Characterization and outcomes of 51 patients', Rheumatology, VOL. 60, Numéro 6, p. 2946-2957. https://doi.org/10.1093/rheumatology/keaa748

TY - JOUR

T1 - SARS-CoV-2 infection in patients with primary Sjögren syndrome

T2 - Characterization and outcomes of 51 patients

AU - Brito-Zerón, Pilar

AU - Melchor, Sheila

AU - Seror, Raphaèle

AU - Priori, Roberta

AU - Solans, Roser

AU - Kostov, Belchin

AU - Baldini, Chiara

AU - Carubbi, Francesco

AU - Callejas, Jose Luis

AU - Guisado-Vasco, Pablo

AU - Hernández-Molina, Gabriela

AU - Pasoto, Sandra G.

AU - Valim, Valeria

AU - Sisó-Almirall, Antoni

AU - Mariette, Xavier

AU - Carreira, Patricia

AU - Ramos-Casals, Manuel

AU - Brito-Zerón, P.

AU - Morcillo, C.

AU - Brito-Zerón, P.

AU - Flores-Chávez, A.

AU - Acar-Denizli, N.

AU - Horvath, I. F.

AU - Szanto, A.

AU - Tarr, T.

AU - Seror, R.

AU - Mandl, T.

AU - Olsson, P.

AU - Li, X.

AU - Xu, B.

AU - Baldini, C.

AU - Bombardieri, S.

AU - Gottenberg, J. E.

AU - Gandolfo, S.

AU - De Vita, S.

AU - Priori, R.

AU - Giardina, F.

AU - Hernandez-Molina, G.

AU - Sánchez-Guerrero, J.

AU - Kruize, A. A.

AU - Hinrichs, A.

AU - Valim, V.

AU - Isenberg, D.

AU - Solans, R.

AU - Rischmueller, M.

AU - Downie-Doyle, S.

AU - Kwok, S. K.

AU - Park, S. H.

AU - Nordmark, G.

AU - Suzuki, Y.

AU - Kawano, M.

AU - Giacomelli, R.

AU - Devauchelle-Pensec, V.

AU - Saraux, A.

AU - Hofauer, B.

AU - Knopf, A.

AU - Bootsma, H.

AU - Vissink, A.

AU - Morel, J.

AU - Vollenveider, C.

AU - Atzeni, F.

AU - Retamozo, S.

AU - Moça Trevisano, V.

AU - Armagan, B.

AU - Kilic, L.

AU - Kalyoncu, U.

AU - Pasoto, S. G.

AU - Kostov, B.

AU - Sisó-Almirall, A.

AU - Consani-Fernández, S.

AU - Carubbi, F.

AU - Callejas, J. L.

AU - López-Dupla, M.

AU - Pérez-Alvarez, R.

AU - Akasbi, M.

AU - Sánchez, I.

N1 - Publisher Copyright: © 2020 The Author(s) 2020. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected].

PY - 2021/6/1

Y1 - 2021/6/1

N2 - Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.

AB - Objective: To analyse the prognosis and outcomes of SARS-CoV-2 infection in patients with primary SS. Methods: We searched for patients with primary SS presenting with SARS-CoV-2 infection (defined following and according to the European Centre for Disease Prevention and Control guidelines) among those included in the Big Data Sjögren Registry, an international, multicentre registry of patients diagnosed according to the 2002/2016 classification criteria. Results: A total of 51 patients were included in the study (46 women, mean age at diagnosis of infection of 60 years). According to the number of patients with primary SS evaluated in the Registry (n = 8211), the estimated frequency of SARS-CoV-2 infection was 0.62% (95% CI 0.44, 0.80). All but two presented with symptoms suggestive of COVID-19, including fever (82%), cough (57%), dyspnoea (39%), fatigue/myalgias (27%) and diarrhoea (24%), and the most frequent abnormalities included raised lactate dehydrogenase (LDH) (88%), CRP (81%) and D-dimer (82%) values, and lymphopenia (70%). Infection was managed at home in 26 (51%) cases and 25 (49%) required hospitalization (five required admission to ICU, four died). Compared with patients managed at home, those requiring hospitalization had higher odds of having lymphopenia as laboratory abnormality (adjusted OR 21.22, 95% CI 2.39, 524.09). Patients with comorbidities had an older age (adjusted OR 1.05, 95% CI 1.00, 1.11) and showed a risk for hospital admission six times higher than those without (adjusted OR 6.01, 95% CI 1.72, 23.51) in the multivariate analysis. Conclusion: Baseline comorbidities were a key risk factor for a more complicated COVID-19 in patients with primary SS, with higher rates of hospitalization and poor outcomes in comparison with patients without comorbidities.

KW - COVID-19

KW - Primary SS

KW - SARS-Cov-2

KW - comorbidities

KW - outcomes

UR - http://www.scopus.com/inward/record.url?scp=85108742062&partnerID=8YFLogxK

U2 - 10.1093/rheumatology/keaa748

DO - 10.1093/rheumatology/keaa748

M3 - Article

C2 - 33316070

AN - SCOPUS:85108742062

SN - 1462-0324

VL - 60

SP - 2946

EP - 2957

JO - Rheumatology

JF - Rheumatology

IS - 6

ER -